- Home
- BRSP vs ANAB Comparison
BRSP vs ANAB Comparison
Compare BRSP & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRSP
- ANAB
- Stock Information
- Founded
- BRSP 2017
- ANAB 2005
- Country
- BRSP United States
- ANAB United States
- Employees
- BRSP N/A
- ANAB N/A
- Industry
- BRSP Real Estate Investment Trusts
- ANAB Biotechnology: Pharmaceutical Preparations
- Sector
- BRSP Real Estate
- ANAB Health Care
- Exchange
- BRSP Nasdaq
- ANAB Nasdaq
- Market Cap
- BRSP 764.4M
- ANAB 659.6M
- IPO Year
- BRSP 2018
- ANAB 2017
- Fundamental
- Price
- BRSP $5.10
- ANAB $29.87
- Analyst Decision
- BRSP Buy
- ANAB Buy
- Analyst Count
- BRSP 3
- ANAB 10
- Target Price
- BRSP $6.00
- ANAB $50.63
- AVG Volume (30 Days)
- BRSP 678.3K
- ANAB 737.6K
- Earning Date
- BRSP 10-28-2025
- ANAB 11-04-2025
- Dividend Yield
- BRSP 12.48%
- ANAB N/A
- EPS Growth
- BRSP N/A
- ANAB N/A
- EPS
- BRSP N/A
- ANAB N/A
- Revenue
- BRSP $335,107,000.00
- ANAB $123,164,000.00
- Revenue This Year
- BRSP N/A
- ANAB $11.40
- Revenue Next Year
- BRSP $6.74
- ANAB $8.17
- P/E Ratio
- BRSP N/A
- ANAB N/A
- Revenue Growth
- BRSP N/A
- ANAB 304.17
- 52 Week Low
- BRSP $4.16
- ANAB $12.21
- 52 Week High
- BRSP $6.45
- ANAB $36.54
- Technical
- Relative Strength Index (RSI)
- BRSP 23.43
- ANAB 69.32
- Support Level
- BRSP $5.34
- ANAB $30.00
- Resistance Level
- BRSP $5.51
- ANAB $32.24
- Average True Range (ATR)
- BRSP 0.11
- ANAB 2.08
- MACD
- BRSP -0.07
- ANAB 0.91
- Stochastic Oscillator
- BRSP 6.58
- ANAB 74.83
About BRSP BrightSpire Capital Inc.
BrightSpire Capital Inc is an internally-managed commercial real estate credit REIT focused on originating, acquiring, financing and managing a diversified portfolio of commercial real estate debt and net lease real estate investments predominantly in the United States. CRE debt investments consist of first mortgage loans with the objective of generating consistent risk-adjusted returns. The operating segments of the company are Senior and Mezzanine Loans and Preferred Equity, Net Leased and Other Real Estate, Corporate and Other. Geographically, the company generates revenue from the United States.
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).